CHARLES RIVER LABS INTL INC.

ISIN: US1598641074 WKN: 159864107 Asset Class: Stock



Company Profile

Other liabilities

Tax Expense Rate

Total assets

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Financial figures, Fiscal year: from 31.12. to 30.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 1,608,662,000 1,439,032,000 1,274,095,000 Common stock capital 505.000 513,000 509.000 5,750,197,000 **Fixed assets** 6 586 339 000 6.163.738.000 Equity capital of a company 3,658,998,000 3,023,505,000 2,591,992,000 282,574,000 240,104,000 245,237,000 Cash and cash equivalents **Accrued liabilities** 44,100,000 148,001,000 Other assets **Current liabilities** 1,055,082,000 1,091,585,000 1,033,185,000 Prepayments and accrued income Non-current liabilities 3.480.921.000 3.487.680.000 3.399.115.000 Different income

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAF
Employees	21,800	21,400	20,000
Equity ratio	45.41%	40.39%	37.71%
Debt-equity ratio	120.23%	147.59%	165.15%

223.191.000

8 195 001 000

7.602.770.000

8 195 001 000

130,722,000

7 024 292 000

2022

20.93%

7 602 770 000

2023

17 36%

Company report:	CHADIES	DIVED	I ARC INITI	INIC

2021

17 03%

94.858.000

7 024 292 000

CHARLES RIVER LABS INTL INC.

ISIN: US1598641074 WKN: 159864107 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,129,409,000	3,976,060,000	3,540,160,000
Net income	474,624,000	486,226,000	390,982,000
EBIT	654,776,243	671,689,506	540,227,741
Operating income before taxes	581,284,000	622,987,000	480,710,000
Cash Flow	683,898,000	619,640,000	760,799,000
Net interest income	-131,514,000	-108,223,000	-107,389,000
Research and development expenses	-	-	-
Income taxes	100,914,000	130,379,000	81,873,000
Result from investments in subsidaries, associates and other	-	-	0
Revenues per employee	174,003	170,673	162,600

Board of Directors

Members of Management Board				
Craig Thompson	Member of Board of Directors			
Deborah Kochevar	Member of Board of Directors			
Martin MacKay	Member of Board of Directors			
Nancy Andrews	Member of Board of Directors			
George Llado	Member of Board of Directors			
George Massaro	Member of Board of Directors			
Reshema Kemps-Polanco	Member of Board of Directors			
Richard Wallman	Member of Board of Directors			
Robert Bertolini	Member of Board of Directors			
Virginia Wilson	Member of Board of Directors			
James Foster	Chairman of Managing Board			
Birgit Girshick	Member of Executive Committee			
Flavia Pease	Member of Executive Committee			
Gina M. Mullane	Member of Executive Committee			
John C. Ho	Member of Executive Committee			
Julie Frearson	Member of Executive Committee			
Kristen M. Eisenhauer	Member of Executive Committee			
Mark Mintz	Member of Executive Committee			
Matthew L. Daniel	Member of Executive Committee			
Michael G. Knell	Member of Executive Committee			
Victoria L. Creamer	Member of Executive Committee			